Posts by Mourabit Halima

Pancreatic cancer, often called the “king of cancers,” remains a formidable disease with poor patient outcomes. Challenges stem from the complexity and invasiveness of surgical procedures and limited progress in systemic therapies, which are still largely chemotherapy-based. However, 2024 brought new developments in pancreatic minimally invasive surgery and innovative treatment strategies. In an interview with Oncology Frontier, Dr. Xianjun Yu from Fudan University Shanghai Cancer Center shared his perspective on these advancements, highlighting the refinement of surgical techniques and the emergence of precision medicine approaches for pancreatic cancer.

Editor's Note: The emergence of targeted therapy has ushered in an era of precision medicine for non-small cell lung cancer (NSCLC), leveraging specific targets on tumor cells to block growth…

Editor’s Note: The European Society for Medical Oncology (ESMO) Asia Annual Meeting was held in Singapore, focusing on the latest oncology advancements in Asia. This conference provided a platform for…

Editor’s Note: In recent years, breakthroughs in new drugs and therapeutic targets for gastrointestinal tumors have brought renewed hope for patients. At the 2024 European Society for Medical Oncology Asia…

Editor's Note: In recent years, advancements in immunotherapy and targeted therapy have significantly contributed to a more personalized and precise approach to the treatment of advanced gastric cancer. As the…

Editor’s Note: Prostate cancer is one of the most prevalent malignant tumors in men worldwide. For localized cases, radical prostatectomy or radiotherapy can achieve a cure, but some patients experience…

Since the release of the CSCO Renal Cancer Diagnosis and Treatment Guidelines in 2013, the guidelines have undergone eight updates, significantly advancing the standardization of renal cancer management in China. Over the past year, significant progress has been made globally and domestically in renal cancer treatment, particularly in medical therapies that have influenced clinical practice. In light of this, the CSCO Renal Cancer Expert Committee discussed and revised the 2024 edition of the guidelines. At the recent 14th Shanghai Urological Oncology Academic Conference and Annual Meeting of the Chinese Anti-Cancer Association Male Reproductive System Oncology Committee (CACA-GO), Dr. Guohai Shi from Fudan University Shanghai Cancer Center provided an in-depth interpretation of the updated guidelines. Below is a summary of his insights.

Focus on clinical priorities, summarize global advancements – the 2024 Lung Cancer Precision Therapy Academic Conference was held on December 15 in Shenzhen. Organized by the Southern Branch of the…

At the recent San Antonio Breast Cancer Symposium (SABCS), Professor Jiong Wu from Fudan University Shanghai Cancer Center presented the latest findings from a Phase I study on SIM0270 (Abstract Number: PS14-03). SIM0270, an innovative brain-penetrant oral selective estrogen receptor degrader (SERD), demonstrated significant clinical efficacy and excellent tolerability in patients with ER+/HER2- advanced breast cancer. Oncology Frontier invited the study’s leading investigator, Dr. Qingyuan Zhang from Harbin Medical University Cancer Hospital, to provide an in-depth interpretation of the results and share insights on future research directions.